The Global Human Plasma Derivative Market was valued at USD 29.8 Billion in 2023 and is projected to reach USD 43.5 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.6% during the forecast period (2024–2030). This robust growth is being driven by increasing prevalence of immunodeficiency disorders, rising demand for coagulation factors in hemophilia treatment, and the accelerated adoption of immunoglobulin therapies across neurology, immunology, and hematology applications.

As the biopharmaceutical industry advances toward targeted and effective therapeutic solutions, the focus is on the key plasma companies who are driving innovation, fractionation technologies, and patient-centric care pathways. In this comprehensive analysis, we profile the Top 10 Companies in the Human Plasma Derivative Industry—a mix of global biotech leaders, fractionation specialists, and plasma therapy pioneers shaping the future of global healthcare.

---

🔟 1. CSL Behring

Headquarters: King of Prussia, Pennsylvania, USA
Key Offering: Immunoglobulins, Albumin, Coagulation Factors, and Alpha-1-Proteinase Inhibitor

CSL Behring is a global leader in plasma-derived therapies, operating one of the world’s largest and most sophisticated plasma collection networks. Their portfolio includes treatments for immunodeficiency, bleeding disorders, and neurological conditions, with significant investments in next-generation plasma fractionation technologies and recombinant alternatives.

Innovation Initiatives:

• Advanced plasma collection and testing protocols

• Strategic partnerships with healthcare providers and patient organizations

• Commitment to plasma supply chain resilience and patient access

Download FREE Sample Report: Human Plasma Derivative Market – View in Detailed Research Report

---

9️⃣ 2. Baxalta (Takeda)

Headquarters: Zurich, Switzerland (Part of Takeda Pharmaceutical Company)
Key Offering: Immunoglobulins, Recombinant Coagulation Factors, Plasma-derived Therapies

Baxalta, now integrated into Takeda, maintains a robust plasma-derived medicine portfolio focused on immunology, hematology, and complex chronic conditions. The company operates extensive plasma collection networks across North America and Europe.

Innovation Initiatives:

• Global plasma collection center expansion

• Research into extended half-life products and novel indications

---

8️⃣ 3. Grifols

Headquarters: Barcelona, Spain
Key Offering: Albumin, Intravenous Immunoglobulin (IVIG), Alpha-1 Antitrypsin

Grifols operates one of the most vertically integrated plasma businesses globally, with over 380 plasma donation centers. Their comprehensive portfolio addresses therapeutic areas including immunology, pulmonology, and critical care.

Innovation Initiatives:

• Investment in next-generation fractionation technologies

• Diagnostics division supporting plasma safety and quality

---

7️⃣ 4. Octapharma

Headquarters: Lachen, Switzerland
Key Offering: Human Cell Line Recombinant Factor VIII, IVIG, von Willebrand Factor

Octapharma is a family-owned company with significant global presence in plasma proteins. They operate state-of-the-art fractionation facilities in Austria, France, and Germany.

Innovation Initiatives:

• Proprietary plasma purification technologies

• Focus on orphan diseases and rare conditions

Download FREE Sample Report: Human Plasma Derivative Market – View in Detailed Research Report

---

6️⃣ 5. Baxter International

Headquarters: Deerfield, Illinois, USA
Key Offering: Albumin, Coagulation Factors, Immunoglobulins

Baxter’s BioScience business manufactures plasma-based and recombinant hemophilia therapies, alongside critical care products for hospitals and clinical settings.

Innovation Initiatives:

• Advanced viral inactivation technologies

• Global manufacturing and distribution network

---

5️⃣ 6. SK Plasma

Headquarters: Seoul, South Korea
Key Offering: Human Albumin, Immunoglobulins, Coagulation Concentrates

SK Plasma is a leading biopharmaceutical company in Asia, specializing in plasma-derived medicines. They have strategic partnerships with global plasma companies to expand their therapeutic reach.

Innovation Initiatives:

• Expansion of plasma collection infrastructure in Asia-Pacific

• Development of hyperimmune globulins for emerging infectious diseases

---

4️⃣ 7. Fusion Health Care

Headquarters: Mumbai, India
Key Offering: Albumin, IVIG, Coagulation Factor VIII

Fusion Health Care has emerged as a significant player in plasma fractionation, particularly serving emerging markets with essential plasma-derived therapies.

Innovation Initiatives:

• Focus on affordable plasma protein solutions

• Strategic focus on biosimilars and generic biotherapeutics

---

3️⃣ 8. Beijing Tiantan Biological Products Corporation

Headquarters: Beijing, China
Key Offering: Human Albumin, Immunoglobulins, Coagulation Products

Beijing Tiantan is one of China’s leading plasma product manufacturers, with a growing network of plasma collection stations and state-of-the-art manufacturing facilities.

Innovation Initiatives:

• Rapid expansion of plasma collection capacity in China

• Government-backed initiatives to achieve plasma self-sufficiency

---

2️⃣ 9. Hualan Biological

Headquarters: Xinxiang, Henan, China
Key Offering: Albumin, Immunoglobulin, Coagulation Factor VIII

Hualan Biological has significantly expanded its plasma collection network in recent years, positioning itself as a key domestic plasma supplier in China’s rapidly growing healthcare market.

Innovation Initiatives:

• Investment in plasma fractionation technology transfer

• Participation in national plasma reserve programs

---

1️⃣ 10. Shanghai RAAS Blood Products

Headquarters: Shanghai, China
Key Offering: Albumin, Immunoglobulin, Coagulation Concentrates

Shanghai RAAS is a major player in China’s plasma industry, with extensive experience in blood product manufacturing and quality control systems.

Innovation Initiatives:

• Strategic alliances with international plasma companies

• Development of plasma-derived products for specific therapeutic applications in the Chinese market.

Get Full Report Here: Human Plasma Derivative Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Human Plasma Derivatives Is More Advanced and Accessible

The human plasma derivative market is undergoing a significant evolution. While traditional plasma products continue to dominate therapeutic applications, the industry is investing substantially in novel fractionation technologies, recombinant alternatives, and global supply chain optimization.

📈 Key Trends Shaping the Market:

• Rapid expansion of plasma collection infrastructure in Asia-Pacific and Latin America

• Regulatory harmonization efforts to facilitate global plasma product distribution

• Technological advancements in pathogen reduction and product safety

• Increasing focus on hyperimmune globulins for pandemic preparedness

• Development of subcutaneous immunoglobulin formulations for improved patient convenience

Download FREE Sample Report: Human Plasma Derivative Market – View in Detailed Research Report

The companies listed above are not only providing lifesaving therapies—they’re advancing the therapeutic frontiers of modern medicine.

Get Full Report Here: Human Plasma Derivative Market – View in Detailed Research Report